Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)
Yi-Long Wu, Wenzhao Zhong, Qun Wang, et al.
Magdalena Jurkiewicz, Anjali Saqi, Mahesh M Mansukhani, et al.
P.K. Paik and Others
9069 RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.
David R. Spigel, Luis G. Paz-Ares, Yuanbin Chen, et al.
The abstract concludes:
ORR and DCR12wks were numerically higher in platinum-sensitive than in platinum-resistant patients with SCLC who had progressed with platinum-based 1L therapy before receiving 2L liposomal irinotecan 70 mg/m2 in this phase 2 study. RESILIENT part 2, an ongoing, phase 3, randomized controlled trial vs topotecan, will provide further data. Clinical trial information: NCT03088813CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
TPS9081 RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.
Luis G. Paz-Ares, David R. Spigel, Yuanbin Chen, et al.
- The primary endpoint is overall survival (OS) and secondary endpoints are progression-free survival (PFS), objective response rate, and proportion of patients reporting symptom improvement.
Clinical trial information: NCT03088813
Top presentations and expert interviews now available on demand!
Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology"
ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries.
Lung (Abstracts #LBA5, 9000, 9001)
Access Content Now